Locus of control flip: management says the outcome is in its own hands, and names what it controls
The model's full reasoning — Q1 2017 call → NOWe need to determine if management conveys that future results are determined mainly by things the company controls, and backs it with a specific, nameable driver already real today. Let's analyze the transcript. The CEO Tom Joyce and CFO Dan Comas speak. They discuss Q1 results and guidance. Key points: - They mention "we drove share gains" and "continued to reinvest in our businesses to enhance our long-term growth trajectory." They talk about innovation and commercial initiatives. - They discuss specific drivers: Pall and Cepheid performing well, new product launches like Biomek i-Series, Cepheid's Xpert Xpress flu/RSV test, AVT acquisition, etc. - They mention "we feel well-positioned to benefit from compelling market drivers" but also emphasize their own execution. But the question is about the coming periods. Do they say that future results are determined mainly by their own actions? They do mention that they expect second quarter core revenue growth comparable to first quarter, and full-year guidance. They discuss investments and DBS. However, they also attribute some softness to external factors like dental consumables market weakness, currency, etc. But they also say they are taking cost out and investing. Let's look for a specific statement where they say the outcome is in their own hands. For example, they talk about "we continue to focus primarily on small and midsized acquisitions" and "we will continue to benefit from long-term trends" but that's external. They mention "we feel very well-positioned to take advantage of these going forward" but that's about market drivers. They also say "we see tremendous opportunities to enhance our growth and margin profile through focused execution across the portfolio." That's a stance of self-determination. But do they name a specific controllable driver already in motion? They mention Cepheid's double-digit growth and margin expansion due to DBS, they mention new product launches, they mention the AVT acquisition, they mention the Biomek i-Series launch, they mention the CM130 coring system, etc. These are specific actions already taken. But the question is about the coming periods. They say "we are initiating second quarter adjusted diluted net EPS guidance" and "we continue to expect full-year" - they don't explicitly say that the future is determined by their own actions rather than market conditions.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| SFIX | Stitch Fix, Inc. | Q3 2024 | 2024-06-04 | C+ |
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| TNET | TriNet Group, Inc. | Q1 2024 | 2024-04-26 | C |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| GPRO | GoPro, Inc. | Q4 2023 | 2024-02-07 | F |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TSSI | TSS, Inc. | Q4 2022 | 2023-04-03 | D |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| CLVT | Clarivate Plc | Q2 2021 | 2021-07-31 | B+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| ASND | Ascendis Pharma A/S | Q1 2018 | 2018-05-30 | C+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| SCVL | Shoe Carnival, Inc. | Q4 2017 | 2018-03-27 | C+ |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| UNH | UnitedHealth Group Incorporated | Q4 2017 | 2018-01-16 | A |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| STKL | SunOpta Inc. | Q2 2017 | 2017-08-09 | C+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
| MRIN | Marin Software Incorporated | Q4 2016 | 2017-02-28 | D |
| SXT | Sensient Technologies Corporation | Q4 2016 | 2017-02-10 | A |
| ATO | Atmos Energy Corporation | Q1 2017 | 2017-02-08 | A |
| EFSC | Enterprise Financial Services Corp | Q4 2016 | 2017-01-24 | B+ |
| RPM | RPM International Inc. | Q2 2017 | 2017-01-05 | D |
| LEE | Lee Enterprises, Incorporated | Q4 2016 | 2016-12-09 | C |
| FATE | Fate Therapeutics, Inc. | Q3 2016 | 2016-11-07 | C |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GIS | General Mills, Inc. | Q4 2016 | 2016-06-29 | B+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
TNET · Q1 2024 → YESThe question is: Does management convey that the company's results over the coming periods will be determined mainly by THINGS THE COMPANY ITSELF CONTROLS, rather than by market conditions, etc., AND ...YES The transcript shows management framing future results as largely self-determined through internal levers like offsetting attrition with new sales (which they expect to "consistently achieve"), disciplined execution in sales/retention/expenses, and a strategy review to align resources for profitable growth. They back this with specific, already-real drivers: 50 % YoY ACV new sales growth, 28 % YoY growth in tenured sales reps plus productivity gains, and nearly positive sequential core WSE growth in Q1. While acknowledging external headwinds (economic hiring softness, insurance cost inflation), they repeatedly redirect to what they control and point to these internal actions as the primary drivers of improvement. The stance is coherent and not generic. Answer: YES. The question requires "mainly" and "rather than by market conditions, etc."; the transcript meets that threshold by repeatedly emphasizing internal control and execution while treating external factors as secondary headwinds they are managing.
GPRO · Q4 2023 → YESThe question is: Does management convey that the company's results over the coming periods will be determined mainly by THINGS THE COMPANY ITSELF CONTROLS, rather than by market conditions, etc., AND ...YES The transcript shows management framing 2024 results as driven primarily by its own actions: the retail expansion already underway (3,200 doors added, 7,000 targeted), new product launches (four SKUs in 2024), the Forcite acquisition closed this quarter, and the Quik desktop app launched 24 hours ago. They repeatedly tie future growth to these internal levers rather than external demand or macro conditions, while noting external factors only as temporary Q4 headwinds. This meets both criteria. NO if it were mainly external or generic. YES. The stance is coherent and backed by a named, already-real driver (ret 3200 doors + strategy shift). The answer is YES. The question is answered with YES. The final answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES.
HROW · Q4 2021 → YESThe question is: Does management convey that the company's results over the coming periods will be determined mainly by THINGS THE COMPANY ITSELF CONTROLS, rather than by market conditions, etc., AND ...YES The transcript shows management framing the path ahead as substantially self-determined through its own execution and actions (e.g., "positioning Harrow Health to fulfill its vision," "executing on that vision," "we are expanding our existing commercial infrastructure," "establishing our own internal analytical lab," "we expect to see 2023 number looks like 2024, 2025" via "profits that this team has been able to generate," and "we have that amazing commercial team and we have a large customer base" for launches without dilution). They redirect from external factors like COVID to internal progress and state they will "not dilute our shareholders necessarily to launch AMP-100" due to internal capabilities.